Compare · CI vs LH
CI vs LH
Side-by-side comparison of The Cigna Group (CI) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 3.5x LH ($21.74B).
- Over the past year, CI is down 7.1% and LH is up 3.0% - LH leads by 10.1 points.
- LH has been more active in the news (7 items in the past 4 weeks vs 4 for CI).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Labcorp Holdings Inc.
- Price
- $289.26-0.08%
- $263.50-0.60%
- Market cap
- $76.58B
- $21.74B
- 1M return
- +1.86%
- +2.15%
- 1Y return
- -7.08%
- +3.03%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 7
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest LH
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Present at the Jefferies Global Healthcare Conference
- Labcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Labcorp Holdings Inc.
- Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
- President & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)
- Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
- SEC Form 144 filed by Labcorp Holdings Inc.